Product Description
DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02514213)
Mechanisms of Action: DNA Immuno
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PCa-001 | P1 |
Completed |
Prostate Cancer |
2017-12-12 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2020 |
News Article |
Prostate Specific Antigen - Pipeline Review, H2 2019 - ResearchAndMarkets.com |
|
01/06/2020 |
News Article |
Inovio Provides Update on Clinical Program Plans for 2020 |